IMNN

Imunon, Inc.

Price Chart

Latest Quote

$1.77

+0.02 (+1.14%)

Current Price

Previous Close	$1.75
Open	$1.83
Day High	$1.83
Day Low	$1.75
Volume	17,486

Fetched: 2026-06-25T15:05:25

Stock Information

Shares Outstanding	4.20M
Total Debt	$912K
Cash Equivalents	$4.79M
Net Income	$-14.64M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$7.44M
EPS (TTM)	$-4.52
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$3.39M
Income	$-14.64M
Book/sh	$0.67
Cash/sh	$1.14
Employees	20

Financial Ratios

Quick Ratio	1.15
Current Ratio	1.59
Debt/Eq	27.14

Returns & Margins

ROA	-124.42%
ROE	-768.25%

Ownership

Insider Ownership	1.60%
Institutional Ownership	11.99%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-0.81
PEG	5.03
P/B	2.65

Analyst Data

Recommendation	none
Target Price	$17.00

Technical Indicators

SMA20	$1.98
SMA50	$2.40
SMA200	$3.54
RSI	18.87
ATR	0.1386

Shares Float	3.77M
Short Float	1.38%
Short Ratio	1.17
Volatility	1.93
Rel Volume	0.25

Performance History

Week	-4.84%
Month	-19.55%
Quarter	-36.33%
6 Months	-52.55%
YTD	-55.19%
Year	-84.75%
3 Years	-89.64%
5 Years	-99.31%
10 Years	-99.95%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-25	$1.77	17,486
2026-06-24	$1.73	62,900
2026-06-23	$1.78	82,600
2026-06-22	$1.80	18,400
2026-06-18	$1.82	34,400
2026-06-17	$1.86	455,300
2026-06-16	$1.88	57,600
2026-06-15	$1.95	29,000
2026-06-12	$2.02	46,000
2026-06-11	$2.03	19,900
2026-06-10	$1.98	52,700
2026-06-09	$2.02	33,600
2026-06-08	$2.01	83,700
2026-06-05	$2.06	84,600
2026-06-04	$2.10	61,700
2026-06-03	$2.10	34,300
2026-06-02	$2.14	51,800
2026-06-01	$2.15	60,900
2026-05-29	$2.18	87,700
2026-05-28	$2.30	52,400
2026-05-27	$2.30	87,900
2026-05-26	$2.20	114,300

About Imunon, Inc.

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

📰 Latest News

Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)

InvestorsHub • 2026-06-04T14:32:14Z

Imunon IMNN Q4 2025 Earnings Transcript

Motley Fool • 2026-06-01T15:47:00Z

Imunon Inc (IMNN) Q1 2026 Earnings Call Highlights: Promising Clinical Progress Amidst Funding ...

GuruFocus.com • 2026-05-12T23:00:33Z

Imunon (IMNN) Q1 2026 Earnings Transcript

Motley Fool • 2026-05-12T16:13:32Z

Imunon, Inc. Q4 2025 Earnings Call Summary

Moby • 2026-04-01T12:30:00Z

Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Management

GuruFocus.com • 2026-03-31T21:00:30Z

Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and ...

GuruFocus.com • 2025-11-13T23:01:17Z

Imunon (IMNN) Q3 2025 Earnings Call Transcript

Motley Fool • 2025-11-13T18:49:30Z

Imunon Inc (IMNN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com • 2025-08-06T07:20:40Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$500,000
Operating Revenue	$0	$0	$0	$500,000
Expenses
Total Expenses	$14,650,694	$19,132,446	$21,030,430	$25,421,565
Other Income Expense	$155,666	$512,204	$-293,676	$-8,017,655
Operating Expense	$14,650,694	$19,132,446	$21,030,430	$25,421,565
General And Administrative Expense	$6,869,996	$7,493,035	$9,742,739	$13,687,899
Interest Expense	-	$0	$197,080	$5,028,618
Net Non Operating Interest Income Expense	-	$450,221	$528,744	$-4,526,040
Interest Expense Non Operating	-	$0	$197,080	$5,028,618
Other Non Operating Income Expenses	-	-	$-396,319	$1,801
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-14,495,028	$-18,620,242	$-19,514,977	$-35,898,234
Normalized Income	$-14,650,694	$-19,132,446	$-19,611,359	$-28,207,576
Net Income From Continuing And Discontinued Operation	$-14,495,028	$-18,620,242	$-19,514,977	$-35,898,234
Total Operating Income As Reported	$-14,650,694	$-19,132,446	$-21,030,430	$-24,921,565
Net Income Common Stockholders	$-14,495,028	$-18,620,242	$-19,514,977	$-35,898,234
Net Income	$-14,495,028	$-18,620,242	$-19,514,977	$-35,898,234
Net Income Continuous Operations	$-14,495,028	$-18,620,242	$-19,514,977	$-35,898,234
Pretax Income	$-14,495,028	$-18,620,242	$-20,795,362	$-37,465,260
Operating Income	$-14,650,694	$-19,132,446	$-21,030,430	$-24,921,565
Net Interest Income	-	$450,221	$528,744	$-4,526,040
Interest Income	-	$450,221	$725,824	$502,578
Special Income Charges	-	$0	$-329,158	$-7,970,234
Interest Income Non Operating	-	$450,221	$725,824	$502,578
Per Share
Diluted EPS	$-6.83	$-21.13	$-28.17	$-65.61
Basic EPS	$-6.83	$-21.13	$-28.17	$-65.61
Other
Tax Effect Of Unusual Items	$0	$0	$6,261	$-328,798
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-14,107,460	$-18,926,534	$-19,980,920	$-23,685,557
Total Unusual Items	$155,666	$512,204	$102,643	$-8,019,456
Total Unusual Items Excluding Goodwill	$155,666	$512,204	$102,643	$-8,019,456
Reconciled Depreciation	$698,900	$718,116	$720,005	$731,629
EBITDA (Bullshit earnings)	$-13,951,794	$-18,414,330	$-19,878,277	$-31,705,013
EBIT	$-14,650,694	$-19,132,446	$-20,598,282	$-32,436,642
Diluted Average Shares	$2,123,344	$882,280	$693,474	$547,630
Basic Average Shares	$2,123,344	$882,280	$693,474	$547,630
Diluted NI Availto Com Stockholders	$-14,495,028	$-18,620,242	$-19,514,977	$-35,898,234
Gain On Sale Of Security	$155,666	$512,204	$431,801	$-49,222
Research And Development	$7,780,698	$11,639,411	$11,287,691	$11,733,666
Selling General And Administration	$6,869,996	$7,493,035	$9,742,739	$13,687,899
Other Gand A	$6,869,996	$7,493,035	$9,742,739	$13,687,899
Tax Provision	-	$0	$-1,280,385	$-1,567,026
Other Special Charges	-	-	$329,158	-
Impairment Of Capital Assets	-	-	$0	$13,366,234
Restructuring And Mergern Acquisition	-	-	$0	$-5,396,000

Fetched: 2026-06-19

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$7,061,876	$4,244,298	$13,387,642	$29,327,866
Total Assets	$12,288,116	$9,717,364	$21,918,069	$43,975,894
Total Non Current Assets	$1,564,372	$1,708,405	$3,677,365	$7,196,203
Other Non Current Assets	$50,000	$50,000	$50,000	$4,925,000
Current Assets	$10,723,744	$8,008,959	$18,240,704	$36,779,691
Other Current Assets	$1,942,685	$2,136,192	$2,545,051	$2,403,433
Cash Cash Equivalents And Short Term Investments	$8,781,059	$5,872,767	$15,695,653	$32,747,326
Cash And Cash Equivalents	$8,781,059	$5,872,767	$5,838,566	$11,492,841
Non Current Deferred Assets	-	$0	$1,280,385	$1,567,026
Non Current Deferred Taxes Assets	-	$0	$1,280,385	$1,567,026
Restricted Cash	-	-	$0	$1,500,000
Receivables	-	-	$0	$128,932
Accrued Interest Receivable	-	-	$0	$128,932
Goodwill And Other Intangible Assets	-	-	-	$0
Non Current Prepaid Assets	-	-	-	-
Prepaid Assets	-	-	-	-
Debt
Total Debt	$1,008,765	$1,139,293	$1,624,714	$6,266,469
Long Term Debt And Capital Lease Obligation	$602,411	$686,935	$1,139,293	$4,610,946
Current Debt And Capital Lease Obligation	$406,354	$452,358	$485,421	$1,655,523
Long Term Debt	-	-	-	$4,610,946
Current Debt	-	-	-	$1,424,774
Other Current Borrowings	-	-	-	$1,424,774
Liabilities
Total Liabilities Net Minority Interest	$5,226,240	$5,473,066	$8,530,427	$14,648,028
Total Non Current Liabilities Net Minority Interest	$602,411	$686,935	$1,139,293	$4,610,946
Current Liabilities	$4,623,829	$4,786,131	$7,391,134	$10,037,082
Payables And Accrued Expenses	$4,217,475	$4,333,773	$6,905,713	$8,381,559
Payables	$1,392,829	$1,300,026	$3,515,192	$3,586,623
Accounts Payable	$1,392,829	$1,300,026	$3,515,192	$3,586,623
Interest Payable	-	-	$0	$37,583
Other Payable	-	-	$1,442,659	$2,196,711
Current Deferred Liabilities	-	-	-	$0
Other Non Current Liabilities	-	-	-	-
Non Current Deferred Liabilities	-	-	-	-
Equity
Common Stock Equity	$7,061,876	$4,244,298	$13,387,642	$29,327,866
Total Equity Gross Minority Interest	$7,061,876	$4,244,298	$13,387,642	$29,327,866
Stockholders Equity	$7,061,876	$4,244,298	$13,387,642	$29,327,866
Retained Earnings	$-421,298,072	$-406,803,044	$-388,182,802	$-368,667,825
Gains Losses Not Affecting Retained Earnings	-	$0	$60,796	$26,494
Other Equity Adjustments	-	-	$60,796	$26,494
Other
Treasury Shares Number	$2	$1	$1	$1
Ordinary Shares Number	$3,419,650	$1,111,719	$720,650	$570,108
Share Issued	$3,419,652	$1,111,720	$720,651	$570,109
Tangible Book Value	$7,061,876	$4,244,298	$13,387,642	$29,327,866
Invested Capital	$7,061,876	$4,244,298	$13,387,642	$35,363,586
Working Capital	$6,099,915	$3,222,828	$10,849,570	$26,742,609
Capital Lease Obligations	$1,008,765	$1,139,293	$1,624,714	$230,749
Total Capitalization	$7,061,876	$4,244,298	$13,387,642	$33,938,812
Treasury Stock	$85,188	$85,188	$85,188	$85,188
Additional Paid In Capital	$428,410,939	$411,122,863	$401,500,838	$397,980,023
Capital Stock	$34,197	$9,667	$93,998	$74,362
Common Stock	$34,197	$9,667	$93,998	$74,362
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$602,411	$686,935	$1,139,293	$0
Current Capital Lease Obligation	$406,354	$452,358	$485,421	$230,749
Current Accrued Expenses	$2,824,646	$3,033,747	$3,390,521	$4,794,936
Net PPE	$1,514,372	$1,658,405	$2,346,980	$704,177
Accumulated Depreciation	$-1,275,941	$-1,196,295	$-2,102,272	$-2,643,762
Leases	$700,149	$619,024	$607,054	$373,194
Other Properties	$984,436	$1,117,133	$1,595,074	$155,876
Machinery Furniture Equipment	$1,105,728	$1,118,543	$2,247,124	$2,818,869
Properties	$0	$0	$0	$0
Other Short Term Investments	-	$0	$9,857,087	$21,254,485
Current Deferred Revenue	-	-	-	$0
Non Current Deferred Revenue	-	-	-	-
Goodwill	-	-	-	-

Fetched: 2026-06-19

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-14,177,196	$-18,884,511	$-19,473,907	$-23,364,695
Operating Activities
Operating Cash Flow	$-13,896,624	$-18,854,970	$-19,022,148	$-23,096,895
Cash Flow From Continuing Operating Activities	$-13,896,624	$-18,854,970	$-19,022,148	$-23,096,895
Operating Gains Losses	-	$-61,983	$363,460	$34,468
Investing Activities
Capital Expenditure	$-280,572	$-29,541	$-451,759	$-267,800
Investing Cash Flow	$-280,572	$9,828,733	$11,006,435	$8,280,810
Cash Flow From Continuing Investing Activities	$-280,572	$9,828,733	$11,006,435	$8,280,810
Financing Activities
Issuance Of Capital Stock	$13,628,070	$9,060,438	$2,781,438	$35,222,654
Financing Cash Flow	$17,085,488	$9,060,438	$-3,638,562	$6,722,654
Cash Flow From Continuing Financing Activities	$17,085,488	$9,060,438	$-3,638,562	$6,722,654
Cash Dividends Paid	$-10,277	$0	-	-
Common Stock Dividend Paid	$-10,277	$0	-	-
Net Common Stock Issuance	$13,628,070	$9,060,438	$2,781,438	$6,722,654
Common Stock Issuance	$13,628,070	$9,060,438	$2,781,438	$6,722,654
Repurchase Of Capital Stock	-	-	$0	$-28,500,000
Net Preferred Stock Issuance	-	-	$0	$0
Preferred Stock Issuance	-	-	$0	$28,500,000
Other
End Cash Position	$8,781,059	$5,872,767	$5,838,566	$17,492,841
Beginning Cash Position	$5,872,767	$5,838,566	$17,492,841	$25,586,272
Changes In Cash	$2,908,292	$34,201	$-11,654,275	$-8,093,431
Proceeds From Stock Option Exercised	$3,467,695	$0	-	$0
Net Investment Purchase And Sale	$0	$9,858,274	$11,458,194	$8,548,610
Sale Of Investment	$0	$9,915,448	$25,000,000	$56,775,000
Purchase Of Investment	$0	$-57,174	$-13,541,806	$-48,226,390
Net PPE Purchase And Sale	$-280,572	$-29,541	$-451,759	$-267,800
Purchase Of PPE	$-280,572	$-29,541	$-451,759	$-267,800
Change In Working Capital	$-327,614	$-2,648,502	$-2,066,412	$1,894,282
Change In Payables And Accrued Expense	$-521,121	$-3,057,361	$-1,992,929	$2,111,901
Change In Prepaid Assets	$193,507	$408,859	$-141,619	$43,980
Other Non Cash Items	$99,744	-	$55,122	$-5,714,741
Stock Based Compensation	$127,374	$477,256	$759,013	$2,673,047
Deferred Tax	$0	$1,280,385	$286,641	$-183,580
Deferred Income Tax	$0	$1,280,385	$286,641	$-183,580
Depreciation Amortization Depletion	$698,900	$718,116	$720,005	$731,629
Depreciation And Amortization	$698,900	$718,116	$720,005	$731,629
Depreciation	$698,900	$718,116	$720,005	$731,629
Net Income From Continuing Operations	$-14,495,028	$-18,620,242	$-19,514,977	$-35,898,234
Repayment Of Debt	-	$0	$-6,420,000	$0
Interest Paid Supplemental Data	-	$0	$179,542	$4,847,359
Net Issuance Payments Of Debt	-	$0	$-6,420,000	$0
Net Long Term Debt Issuance	-	$0	$-6,420,000	$0
Long Term Debt Payments	-	$0	$-6,420,000	$0
Change In Receivables	-	$0	$68,136	$-20,088
Asset Impairment Charge	-	$0	$375,000	$13,366,234
Gain Loss On Investment Securities	-	$-61,983	$34,302	$34,468
Income Tax Paid Supplemental Data	-	-	$2,500	$2,000
Preferred Stock Payments	-	-	$0	$-28,500,000
Change In Other Current Assets	-	-	$0	$-241,511
Issuance Of Debt	-	-	-	$0
Long Term Debt Issuance	-	-	-	$0
Change In Other Working Capital	-	-	-	$-500,000
Change In Accrued Expense	-	-	-	$1,072,529
Change In Payable	-	-	-	$1,039,372
Change In Account Payable	-	-	-	$1,039,372

Fetched: 2026-06-19